Bone Biologics Corporation
NCM: BBLGLive Quote
About Bone Biologics Corporation
Healthcare
Biotechnology
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion by local administration, osteoporosis, and trauma applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
📊 Fundamental Analysis
Bone Biologics Corporation demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -70.2%, which indicates that capital utilization is currently under pressure.
At a current price of $1.26, BBLG currently trades near the bottom of its 52-week range (4%), indicating potential value or weakness (Range: $1.05 - $6.75).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$2.21M
Trailing P/E
--
Forward P/E
-0.78
Beta (5Y)
0.37
52W High
$6.75
52W Low
$1.05
Avg Volume
22K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App